APRINOIA Therapeutics received FDA clearance to initiate APNmA...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
BOSTON, April 11, 2022 /PRNewswire-AsiaNet/ -- APRINOIA Therapeutics announces today that the U.S. Food and Drug Administration (FDA) has granted a may proceed authorization for its novel therapeutic anti-tau monoclonal antibody, APNmAb005, allowing the company to test and evaluate its safety ...
Authors: LATEST ASIANET NEWS RELEASES